Compare Cassava Sciences Inc (FLNA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

FLNA trades at $0.7434, down 3.39% today, with a bearish technical signal despite recent positive FDA news lifting a clinical hold on its epilepsy drug. The company shows improving quarterly EPS beats but remains unprofitable with negative cash flows. Analyst consensus is strongly bullish with 8 buy ratings versus 4 holds.

The outlook hinges on clinical progress—FDA clearance enables Phase 2a trials in 2027, a key catalyst. Risks include sustained cash burn and fiduciary concerns highlighted in recent news. Investors should weigh the high analyst optimism against fundamental weaknesses and regulatory execution risks.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.